Biopharma · FDA Approvals · Stock
PRFX PRF Technologies
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. P…
Assets on file: PRF-110
Catalyst calendar
Dated catalysts for PRFX, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for PRFX, newest first.
PRFXPRF Technologies Ltd.PRF Technologies: PRF-110 matches ZYNRELEF in 72-hour pig pain model
PRF-110 showed comparable 72-hour analgesic activity to the approved ZYNRELEF in a head-to-head preclinical pig incisional pain study. The ropivacaine-only, NSAID-free formulation achieved this result with a safety profile consistent with prior experience. The data are described as supportive for future development and regulatory planning.
PRFXPRF Technologies Ltd.PRF Technologies receives FDA clearance of IND for OcuRing-K Phase II trial
FDA cleared the IND application for OcuRing-K, allowing the company to initiate a U.S. multi-center Phase II clinical trial in patients undergoing cataract surgery. Patient enrollment is expected to begin in the second half of 2026. The clearance advances the program from preclinical to Phase II development.
Peers by market cap
Companies in the same sector closest to PRFX in market value.
ADILAdial PharmaceuticalsMarket cap $2.3M · 1 tracked drug
INMInMed Pharmaceuticals Inc.Market cap $2.4MEEDVAEndovia Health SciencesMarket cap $2.7M
OGENOragenicsMarket cap $2.9M · 1 tracked drugVVBIOValion BioMarket cap $938.2K · 1 tracked drug
MTNBMatinas BioPharmaMarket cap $3.5M
AIMAIM ImmunoTechMarket cap $4.0M · 1 tracked drug · 2 upcoming catalysts
EZRAReliance GlobalMarket cap $4.0M